Our SMAR _xT Tissue-Specific ^TM Platform oncology drug candidates employ our proprietary TME Normalization ^TM Technology. TME Normalization Technology allows our therapies to circulate in the bloodstream, then exit through porous tumor blood vessels, accumulating in the tumor micro-environment, or TME.